Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current opinion in molecular therapeutics (Print)

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  PMID 20521216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

  2010cited by this paper
• Genetic predictors of acute renal transplant rejection.

  2010cited by this paper
• Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.

  2009cited by this paper
• Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism

  2009cited by this paper
• Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Peripheral Blood Mononuclear Cells

  2009cited by this paper
• Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem

  2009cited by this paper
• UGT1A9 −275T>A/−2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus‐Treated Kidney Transplant Patients

  2009cited by this paper
• Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.

  2009cited by this paper
• CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients

  2009cited by this paper
• ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome.

  2009cited by this paper
• The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.

  2009cited by this paper
• Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India

  2009cited by this paper
• Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.

  2009cited by this paper
• Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients.

  2009cited by this paper
• Tacrolimus Concentrations in Relation to CYP3A and ABCB1 Polymorphisms Among Solid Organ Transplant Recipients in Korea

  2009cited by this paper
• CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole

  2009cited by this paper
• Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study

  2009cited by this paper
• Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients

  2008cited by this paper
• Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.

  2008cited by this paper
• Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.

  2008cited by this paper
• Declining Intracellular T-Lymphocyte Concentration of Cyclosporine A Precedes Acute Rejection in Kidney Transplant Recipients

  2008cited by this paper
• Pharmacogenetics of Immunosuppressants: Progress, Pitfalls and Promises

  2008cited by this paper
• Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients

  2008cited by this paper
• No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation.

  2008cited by this paper
• The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans

  2008cited by this paper
• Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients

  2008cited by this paper
• Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.

  2008cited by this paper
• Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation

  2008cited by this paper
• Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients.

  2008cited by this paper
• Association of four DNA polymorphisms with acute rejection after kidney transplantation

  2008cited by this paper
• A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.

  2008cited by this paper
• Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant Recipients

  2008cited by this paper
• ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India.

  2008cited by this paper
• CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients

  2008cited by this paper
• Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial

  2008cited by this paper
• CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients

  2008cited by this paper
• Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients

  2008cited by this paper
• IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients

  2008cited by this paper
• Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.

  2008cited by this paper
• Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients

  2008cited by this paper
• A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity

  2007cited by this paper
• Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients

  2007cited by this paper
• Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate‐binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms

  2007cited by this paper
• From current immunosuppressive strategies to clinical tolerance of allografts

  2007cited by this paper
• Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry.

  2007cited by this paper
• Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL‐10 polymorphisms in adult liver transplant patients

  2007cited by this paper
• Multi‐drug resistance gene‐1 (MDR‐1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements

  2007cited by this paper
• Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.

  2007cited by this paper
• CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal Recipients

  2007cited by this paper
• CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients

  2007cited by this paper
• Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Liver Biopsies After Hepatic Transplantation: Correlation With Histopathologic Staging of Rejection

  2007cited by this paper
• Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation

  2007cited by this paper
• 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation

  2007cited by this paper
• EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO

  2006cited by this paper
• Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

  2006cited by this paper
• Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials

  2006cited by this paper
• Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.

  2006cited by this paper
• The MDR1/ABCB1 Gene, a High-Impact Risk Factor for Cardiac Transplant Rejection

  2006cited by this paper
• Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients

  2006cited by this paper
• CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients

  2006cited by this paper
• Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients.

  2006cited by this paper
• CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study

  2006cited by this paper
• Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living‐donor liver transplant patients

  2006cited by this paper
• The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.

  2006cited by this paper
• Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.

  2006cited by this paper
• The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients.

  2006cited by this paper
• Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients

  2006cited by this paper
• Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements.

  2006cited by this paper
• Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids

  2005cited by this paper
• Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression.

  2005cited by this paper
• Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy

  2005cited by this paper
• Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians

  2005cited by this paper
• Relationship between MDR1 polymorphism and blood concentration of cyclosporine A.

  2005cited by this paper
• Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.

  2005cited by this paper
• ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.

  2005cited by this paper
• Calcineurin Inhibitor–Induced Nephrotoxicity and Renal Expression of P‐glycoprotein

  2005cited by this paper
• Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation

  2005cited by this paper
• Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability

  2005cited by this paper
• Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.

  2005cited by this paper
• The impact of uridine diphosphate–glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single‐nucleotide polymorphisms T—275A and C—2152T on early mycophenolic acid dose‐interval exposure in de novo renal allograft recipients

  2005cited by this paper
• Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

  2005cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression

  2004cited by this paper
• Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients

  2004cited by this paper
• CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1

  2004cited by this paper
• CYP3A variation and the evolution of salt-sensitivity variants.

  2004cited by this paper
• The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation

  2004cited by this paper
• The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients.

  2004cited by this paper
• MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

  2004cited by this paper
• CYP3A5 and MDR1 Genetic Polymorphisms and Cyclosporine Pharmacokinetics After Renal Transplantation

  2004cited by this paper
• Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism

  2004cited by this paper
• Immunosuppressive drugs for kidney transplantation.

  2004cited by this paper
• MDR-1 C3435T Polymorphism Influences Cyclosporine A Dose Requirement in Liver-Transplant Recipients

  2004cited by this paper
• The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.

  2004cited by this paper
• Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy

  2004cited by this paper
• In vitro metabolism of cyclosporine A by human kidney CYP3A5.

  2004cited by this paper
• Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients1

  2003cited by this paper
• Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

  2003cited by this paper
• Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12

  2003cited by this paper
• Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

  2003cited by this paper

• Impacto del polimorfismo MRP2 24ct en el trasplante renal en tratamiento con ácido micofenólico: farmacocinética y repercusión clínica

  2019cites this paper
• 23 Pharmacogenetics of Cancer and DNA Repair Enzymes

  2017cites this paper
• Impact of CYP3A5 and MDR-1 gene polymorphisms on the dose and level of tacrolimus among living-donor liver transplanted patients: single center experience

  2016influential citation
• Associations of HSD11B1 Polymorphisms with Tacrolimus Concentrations in Chinese Renal Transplant Recipients with Prednisone Combined Therapy

  2015cites this paper
• Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population

  2015cites this paper
• Synthesis and biological evaluation of pseudolaric acid B derivatives as potential immunosuppressive agents

  2015cites this paper
• Associations of HSD11B1 Polymorphisms with Tacrolimus Concentrations in Chinese Renal Transplant Recipients with Prednisone Combined Therapy

  2015cites this paper
• Immunosuppression for Kidney Transplantation

  2014cites this paper
• Chapter 20 – Pharmacogenomics

  2014cites this paper
• Drug Interactions in Organ Transplantation

  2014cites this paper
• Clinical and genetic determinants of tacrolimus pharmacokinetics and pharmacodynamics in the transplant population

  2014cites this paper
• DMD047977 480..487

  2013cites this paper
• Utilization of an EMR-Biorepository to Identify the Genetic Predictors of Calcineurin-Inhibitor Toxicity in Heart Transplant Recipients

  2013cites this paper
• SIGNIFICANCE OF CYP 3 A 5 GENE POLYMORPHISM IN SERBIAN RENAL TRANSPLANT PATIENTS

  2013cites this paper
• Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine.

  2013cites this paper
• SIGNIFICANCE OF CYP3A5 GENE POLYMORPHISM IN SERBIAN RENAL TRANSPLANT PATIENTS

  2013cites this paper
• Increased Hospital Stay and Allograft Disfunction in Renal Transplant Recipients with Cyp2c19 AA Variant in SNP rs4244285

  2013cites this paper
• Traditional Therapeutic Drug Monitoring and Pharmacogenomics: Are They Complementary?

  2012cites this paper
• Drug choices in autoimmune hepatitis: Part B – nonsteroids

  2012cites this paper
• Tacrolimus as a part of immunosuppressive treatment in kidney transplantation patients: sex differences.

  2012cites this paper
• Pharmacogenetic biomarkers: cytochrome P450 3A5.

  2012cites this paper
• A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients.

  2012cites this paper
• Rapamycin With Antiretroviral Therapy in AIDS-Associated Kaposi Sarcoma: An AIDS Malignancy Consortium Study

  2012cites this paper
• Pharmacogenomics and the Toxicology Laboratory

  2012cites this paper
• UNIVERSIDADE DE SÃO PAULO FACULDADE DE CIÊNCIAS FARMACÊUTICAS Programa de Pós-Graduação em Farmácia Área de Análises Clínicas Estudo de polimorfismos de MTOR e PPP3CA em receptores de transplante renal e sua relação com a resposta a imunossupressores

  2012cites this paper
• Pharmacogenetics of Cancer and DNA Repair Enzymes

  2011cites this paper
• The clinical value of enzyme-multiplied immunoassay technique monitoring the plasma concentrations of cyclosporine A after renal transplantation

  2011cites this paper
• Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.

  2011cites this paper
• Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.

  2011cites this paper
• Enantioselective Total Synthesis of (–)‐Subglutinols A and B: Potential Immunosuppressive Agents Isolated from a Microorganism

  2011cites this paper
• Proteomics and genomics - toward new research tools

  2010cites this paper
• Laboratory Medicine in the Scope of Proteomics and Genomics

  2010cites this paper
• Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients ReseaRch

  2009cites this paper